AIM
TRAW icon

Acrospire Investment Management’s Traws Pharma TRAW Stock Holding History

Acrospire Investment Management’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1
Closed -$10K – 2537
2016
Q4 		$10K Buy
+1
New +$14.8K ﹤0.01% 1952
2016
Q3 		– Hold
0
– -$5K – 2187
2016
Q2 		– Hold
0
– – – 1868

Other funds holding TRAW

TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acrospire Investment Management's TRAW Position: Q1 2017 in Review

Acrospire Investment Management sold out of Traws Pharma (TRAW) in Q1 2017, closing a stake of 1 share — an estimated $10K sold.

Acrospire Investment Management first reported a position in TRAW in Q4 2016 and held it in 1 quarter. The position peaked at $10K in Q4 2016. 9 funds tracked by Wall St. Rank hold TRAW as of Q1 2017.

  • Acrospire Investment Management reported no remaining Traws Pharma position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1 Traws Pharma share in Q1 2017, an estimated $10K.
  • Acrospire Investment Management first reported a position in Traws Pharma in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Traws Pharma position peaked at $10K in Q4 2016.
  • 9 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.